Hirudin-based anticoagulant strategy during isolated limb perfusion in a patient with heparin-induced thrombocytopenia

Melanoma Research

Volumn 15, Issue 4, 2005, Pages 287-290

  Lindemann, Werner ^a   Richter, Sven ^a   Schilling, Martin K ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Heparin induced thrombocytopenia (HIT); Hirudin; Isolated limb perfusion

Indexed keywords

ECARIN; HEPARIN; LEPIRUDIN; RECOMBINANT HIRUDIN;

AGED; ANAMNESIS; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CASE REPORT; DRUG DOSE REGIMEN; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIMB PERFUSION; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOSIS;

AGED; ANTICOAGULANTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; ENDOPEPTIDASES; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 23744451689     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200508000-00009     Document Type: Article

References (25)

1. Riess FC, Potzsch B, Bader R, Bleese N, Greinacher A, Lower C, et al. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg 1996; 10:386-388.
2. Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77:920-925.
3. Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996; 26:335-349.
4. Masucci IP, Calis KA, Bartlett DL, Alexander HR, Home MK III. Thrombocytopenia after isolated limb or hepatic perfusions with melphalan: the risk of heparin-induced thrombocytopenia. Ann Surg Oncol 1999; 6:476-480.
5. Sandrock D, Horst F, Gatzemeier W, Ghorbani M, Rauschecker H, Munz DL, et al. Leakage measurement during selective limb perfusion using a gamma probe. Eur J Nucl Med 1996; 23:534-538.
6. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148:616-632.
7. Lejeune FJ, Kroon BB, Di FF, Hoekstra HJ, Santinami M, Lienard D, et al. Isolated limb perfusion: the European experience. Surg Oncol Clin North Am 2001; 10:821-832, ix.
8. Beijering RJ, ten Cate H, Nurmohamed MT, ten Cate JW. Anticoagulants and extracorporeal circuits. Semin Thromb Hemost 1997; 23:225-233.
9. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1:1471-1478.
10. Lubenow N, Greinacher A. Hirudin in heparin-induced thrombocytopenia. Semin Thromb Hemost 2002; 28:431-438.
11. Latham P, Revelis AF, Joshi GP, DiMaio JM, Jessen ME. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 2000; 92:263-266.
12. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74:1-23.
13. Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993; 22:364-372.
14. Johnston N, Jessen ME, DiMaio M, Douglass DS. The emergency use of recombinant hirudin in cardiopulmonary bypass. J Extra-Corpor Technol 1999; 31:211-215.
15. Kern H, Ziemer S, Kox WJ. Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med 1999; 25:1311-1314.
16. Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 2000; 14:243-248.
17. Becker RC. Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting. J Thromb Thrombolysis 2000; 10(Suppl. 1):59-68.
18. Longrois D, de Maistre E, Bischoff N, Dopff C, Meistelman C, Angioi M, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anaesth 2000; 47:255-260.
19. Shah AC, Genoni M, Niederhauser U, Maloigne M, Turina M. [R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection]. Schweiz Med Wochenschr 2000; 130:896-899.
20. Fabrizio MC. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra-Corpor Technol 2001; 33:117-125.
21. Liu H, Fleming NW, Moore PG. Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass. J Clin Anesth 2002; 14:452-455.
22. Nuttall GA, Oliver WC Jr, Santrach PJ, McBane RD, Erpelding DB, Marver CL, et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 2003; 96:344-350, table.
23. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl.):311S-337S.
24. Potzsch B, Hund S, Madiener K, Unkrig C, Muller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997; 86:373-383.
25. Riess FC, Potzsch B, Behr I, Jager K, Rossing R, Bleese N, et al. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model. Eur J Cardiothorac Surg 1997; 11:739-745.